He pursued research on the biological applications of magnetic resonance techniques for his PhD in Philosophy at Oxford University, followed by post-doctoral studies in Munich, Germany, and Leeds, England.
[citation needed] He subsequently served as a chairman and chief executive of Molecular Staging,[13] whose genome amplification technology enables gene sequencing on rare DNA samples.
In 2012 with his colleagues at Oxford and UCL, he founded CASMI to develop, test and promote new models of medical innovation, including adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit.
[22] Effective as of December 18, 2020, he resigned from the Board of Directors of 180 Life Sciences Corp, because of other commitments that would not allow him to spend sufficient time on Company matters.
[23] He chairs the charity International Health Partners that brings donated medicines to developing countries, crisis situations and refugee camps.